Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GCAR1 · 1 trial · 2 indications
The overall response assessment considers the response of the target and non-target lesions and development of new lesions. Response Classification of Target Lesions, CNS lesions and Non-Target Lesions * Complete response (CR): * Partial response (PR): * Progressive disease (PD): * Stable disease (SD):
| Arm | Type | Description |
|---|---|---|
| GCAR1 | EXPERIMENTAL | This is an intrapatient two-dose escalation study. The patient will receive two separate intravenous infusions of cryopreserved, autologous GCAR1, with at least three months (+/- 30 days) between infusions. Both infusions will be preceded by standard lymphodepleting chemotherapy (Fludarabine 40 mg/m2 x 3 days, cyclophosphamide 600 mg/m2 x 2 days) . Dose 1 will be 5.0E6 CAR+ T cells/kg patient body weight, Dose 2 will be 2.5E7 CAR+ T cells/kg patient body weight. Infusions will be intravenous, single infusions. |
| Name | Type | Description |
|---|---|---|
| GCAR1 | BIOLOGICAL | GCAR1 is a patient-specific cell therapy product containing a mixture of autologous lymphocytes transduced with a lentiviral vector encoding a chimeric antigen receptor (CAR) targeting GPNMB. The CAR comprises a single-chain variable fragment (scFv) binding domain derived from a fully human GPNMB-specific monoclonal antibody (CDX-011), a CD8 hinge and transmembrane domain, and the CD137 (4-1BB) and CD3 zeta chain intracellular signaling domains. Following infusion, the autologous GPNMB CAR T-cells expressing the genetically engineered anti-GPNMB CAR enable the specific targeting of GPNMB-expressing cells. Upon binding to GPNMB-expressing cells, the CAR transmits T cell activation signals that promote the elimination of target cells through CAR T cell degranulation and the release of cytotoxic molecules. The cellular signal also facilitates CAR T cell proliferation and persistence that may enable prolonged disease control through immunosurveillance3. |
Inclusion Criteria: * The patient must provide informed consent * Adequate organ function, defined as creatinine clearance \>30 ml/min and LVEF \>45% Exclusion Criteria: * Any active uncontrolled infection * Pregnancy or nursing * Anti-cancer therapy within 21 calendar days prior to the first dos...
Top 20 of 30 competitors
GCAR1 is an investigational chimeric antigen receptor (CAR) T cell therapy being developed for the treatment of sarcoma, specifically alveolar soft part sarcoma (ASPS). It is currently in Phase 1 clinical development and is being studied in patients with relapsed disease.
GCAR1 is a monoclonal antibody-based CAR T cell therapy. While the specific molecular target is not disclosed in available information, it is designed to recognize and attack sarcoma cells. The therapy is being evaluated in a biomarker-selected patient population, indicating that target expression is a criterion for enrollment.
GCAR1 is being developed by Precision BioSciences, Inc., a biopharmaceutical company traded on NASDAQ under the ticker symbol DTIL. The company is conducting a Phase 1 clinical trial of GCAR1 in patients with relapsed alveolar soft part sarcoma.
GCAR1 is in Phase 1 clinical development. The ongoing trial is an early Phase 1 study, currently active but not recruiting participants. As an investigational therapy, GCAR1 has not yet been approved by regulatory authorities and remains in clinical testing.
GCAR1 is being evaluated in a single clinical trial registered as NCT06813417, titled 'CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma.' This early Phase 1 study is active but not recruiting, with an enrollment of one participant, and is being conducted in Canada.
GCAR1 is a CAR T cell therapy, but it is a distinct investigational product developed by Precision BioSciences. It is being studied specifically for alveolar soft part sarcoma, a rare soft tissue sarcoma. No alternative names for GCAR1 have been disclosed in available information.